NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis $2.31 +0.10 (+4.43%) Closing price 03:57 PM EasternExtended Trading$2.39 +0.09 (+3.68%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsSEC Filings About XTL Biopharmaceuticals Stock (NASDAQ:XTLB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XTL Biopharmaceuticals alerts:Sign Up Key Stats Today's Range$2.30▼$2.3350-Day Range$2.19▼$3.2352-Week Range$2.01▼$10.28Volume1,561 shsAverage Volume5,259 shsMarket Capitalization$5.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is an Israel-based clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Its research activities have centered on conditions such as systemic lupus erythematosus and multiple sclerosis, where abnormal immune responses can damage healthy tissue. The company’s development programs have included hCDR1, also known as rigerimod, an immunomodulatory peptide investigated as a potential treatment for systemic lupus erythematosus. XTL has also pursued antibody-based programs, including XTL-6865, as part of its broader effort to develop targeted treatments for autoimmune disorders. XTL Biopharmaceuticals has historically operated as an Israeli biotechnology company whose activities have been directed toward international clinical development and potential global commercialization. The company’s programs remain subject to clinical, regulatory and commercial development requirements, and publicly available information about its current leadership and geographic operations is limited.AI Generated. May Contain Errors. Read More XTL Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreXTLB MarketRank™: XTL Biopharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXTL Biopharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXTL Biopharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about XTL Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XTL Biopharmaceuticals is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XTL Biopharmaceuticals is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.43% of the float of XTL Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXTL Biopharmaceuticals has a short interest ratio ("days to cover") of 1.25, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XTL Biopharmaceuticals has recently decreased by 36.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXTL Biopharmaceuticals does not currently pay a dividend.Dividend GrowthXTL Biopharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentXTL Biopharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for XTL Biopharmaceuticals this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.40% of the stock of XTL Biopharmaceuticals is held by institutions.Read more about XTL Biopharmaceuticals' insider trading history. Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XTLB Stock News HeadlinesCritical Contrast: XTL Biopharmaceuticals (NASDAQ:XTLB) vs. Neuphoria Therapeutics (NASDAQ:NEUP)September 25, 2026 | americanbankingnews.comXTL Biopharmaceuticals Ltd. Sponsored ADRJuly 8, 2026 | cnn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 30 at 1:00 AM | Porter & Company (Ad)XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-HoursJuly 1, 2026 | nasdaq.comXTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology PlatformJune 30, 2026 | quiverquant.comQXTL Completed the Acquisition of Psyga Bio Ltd.June 30, 2026 | globenewswire.comXTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026June 23, 2026 | tipranks.comXTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from NasdaqMay 23, 2026 | finanznachrichten.deSee More Headlines XTLB Stock Analysis - Frequently Asked Questions How have XTLB shares performed this year? XTL Biopharmaceuticals' stock was trading at $2.3040 at the start of the year. Since then, XTLB shares have increased by 0.2% and is now trading at $2.3080. How were XTL Biopharmaceuticals' earnings last quarter? XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) posted its earnings results on Monday, December, 30th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter. When did XTL Biopharmaceuticals' stock split? Shares of XTL Biopharmaceuticals reverse split on Wednesday, March 25th 2026.The 1-4 reverse split was announced on Friday, March 20th 2026. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 24th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of XTL Biopharmaceuticals? Shares of XTLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP). Company Calendar Last Earnings12/30/2024Today9/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, XTLB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XTLB CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605Employees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-20.98Miscellaneous Outstanding Shares2,366,000Free Float1,680,000Market Cap$5.46 million OptionableNot Optionable Beta1.38 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:XTLB) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNot SpaceX. Not Tesla. Smaller.SpaceX isn't public, but its paperwork references a company trading for about 14 dollars a share. Roughly 4,40...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
